ArticleAvicenna journal of medical biotechnology2026
Sophoraflavanone G in Nano-Niosomal Form: Implications for Bacterial Inhibition, Biofilm Disruption, and Cancer Suppression.
Article in Avicenna journal of medical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sophoraflavanone G, SG, is a flavonoid compound found in Sophora species with various biological properties, including antibacterial, anticancer, antibio-film activities. However, this compound shows limited solubility in water, which reduces its bioavailability and hinders its practical application. To overcome this barrier, SG nano-niosomal form was prepared. Methods: In the current study, a nano-niosomal form of SG was prepared using cholesterol (Chol) and Tween 20. Antibacterial and antibiofilm activities were assessed by disc and well diffusion and biofilm assays, respectively, while anticancer specificity was evaluated by MTT on KB and L929 cell lines. Results: Disc and well diffusion assays showed a reduction in planktonic antibacterial activity of niosomal SG compared with free SG, whereas biofilm assays improved anti-biofilm effects; MTT assays indicated reduced cytotoxicity toward L929 cells with retained activity against KB cancer cells, suggesting improved anticancer specificity. Conclusion: While niosomal formulation decreased SG's activity against planktonic bacteria, it enhanced antibiofilm effects and improved anticancer specificity by reducing toxicity to normal cells, making niosomal SG a promising candidate for cancer-directed therapeutic applications despite limited antimicrobial gains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.